Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9P2M4
UPID:
TBC14_HUMAN
Alternative names:
-
Alternative UPACC:
Q9P2M4; B9A6L5; D3DVT4; E9PAZ6; Q8IW15; Q8NDK3
Background:
TBC1 domain family member 14 plays a crucial role in autophagy, a process vital for cellular homeostasis by regulating starvation-induced autophagosome formation. It works alongside the TRAPPIII complex to facilitate a key trafficking step from recycling endosomes to the early Golgi, essential for maintaining the ATG9 cycling pool necessary for autophagy initiation.
Therapeutic significance:
Understanding the role of TBC1 domain family member 14 could open doors to potential therapeutic strategies.